72676-80-3

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 73-32-5 L-isoleucine 
• 34235-81-9 3-methyl-2-{[(4-methylphenyl)sulfonyl]amino}pentanoic acid 
• 34235-81-9 3-methyl-2-(4-methylphenylsulfonamido)pentanoic acid 
• 319-78-8 isoleucine 

Downstream Products

• 17086-83-8 β-(DL-N-Tosylisoleucylamino)-propionitril 
• 17087-02-4 β-(DL-N-Tosylisoleucylamino)-propionamid 
• 101740-27-6 N-[N-(toluene-4-sulfonyl)-L-isoleucyl]-glycine ethyl ester 
• 72676-74-5 N-[(1R,2R)-1-(2-Diazo-acetyl)-2-methyl-butyl]-4-methyl-benzenesulfonamide 
• 72676-78-9 N-[(1S,2S)-1-(2-Chloro-acetyl)-2-methyl-butyl]-4-methyl-benzenesulfonamide 

Relevant academic research and scientific papers

Synthesis and structure of lower rim C-linked N-tosyl peptidocalix[4]arenes

Chiral p-tert-butylcalix[4]arenes functionalized at the lower rim with amino acid residues have been prepared. The 1H and 13C NMR spectra indicate that the macrocycles preferably adopt a cone conformation. Calix[4]arenes bearing amin

Isoleucine with secondary sulfonamide functionality as anticancer, antibacterial and antifungal agents

Isoleucine substituted analogues with secondary sulfonamide group (I1–I6) have been synthesized. Structures of synthesized analogues have been confirmed by Fourier Transform-Infrared Red, Nuclear Magnetic Resonance (1H and 13C) and ESI-MS spectroscopic tools. Cytotoxic screenings of synthesized analogues have been done on MCF-7 (breast), Prostate Cancer-3 (PC-3) and A549 (lung) cancer cell lines. N-(1-isobutyl-2-oxo-2-anilinoethyl) p-toluene sulfonamide (I5) screened to be better cytotoxic agent on MCF-7 and A549 cell lines whereas N-(1-isobutyl-2-oxo-2-p-chloroanilino ethyl) benzene sulfonamide (I3) against PC-3 cell line. Cell cycle analysis of N-(1-isobutyl-2-oxo-2-anilinoethyl) p-toluene sulfonamide (I5) analogue has been carried out on A549 cell line in comparison to control and Vinblastine (standard drug). Complete arrest in G0 and G1 phase along with mild disturbance in S-phase of cell cycle has been observed. The screened analogues (I1–I6) also showed good antifungal and antibacterial potential against gram positive as well as gram negative strains. Computer simulation indicated good bioactivity prediction by the ‘Lipinski rule’ and synthesized analogues did not violate this rule. Docking study of isoleucine sulfonamide analogues (I1–I6) were carried out to determine the possible interaction sites of the analogues with p53 tumor suppressor-DNA complex and demonstrate that the analogues confirmed binding and inhibition with the most mutated residues of p53. Density functional theory has been used to correlate the electronic and chemical properties of analogues and they were found to be stable and chemically reactive. Thus the results suggest that isoleucine substituted sulfonamide analogues can serve as a structural model for the design of anticancer agents, antibacterial agents as well as antifungal agents with better inhibitory potential. Communicated by Ramaswamy H. Sarma.